Synthesis and Biological Assessment of Racemic Benzochromenopyrimidinimines as Antioxidant, Cholinesterase, and Aβ<sub>1−42</sub>Aggregation Inhibitors for Alzheimer's Disease Therapy
作者:Youssef Dgachi、Lhassane Ismaili、Damijan Knez、Mohamed Benchekroun、Hélène Martin、Natalia Szałaj、Sarah Wehle、Oscar M. Bautista-Aguilera、Vincent Luzet、Alexandre Bonnet、Barbara Malawska、Stanislav Gobec、Mourad Chioua、Michael Decker、Fakher Chabchoub、José Marco-Contelles
DOI:10.1002/cmdc.201500539
日期:2016.6.20
report an efficient two‐step synthesis and biological evaluation of new racemic benzochromene derivatives as antioxidants, inhibitors of cholinesterase and β‐amyloid (Aβ1−42) aggregation. Based on the results of the primary screening, we identified 15‐(3‐methoxyphenyl)‐9,11,12,15‐tetrahydro‐10H,14H‐benzo[5,6]chromeno[2,3‐d]pyrido[1,2‐a]pyrimidin‐14‐imine (3 e) and 16‐(3‐methoxyphenyl)‐9,10,11,12,13
鉴于阿尔茨海默氏病(AD)的复杂性,能够同时解决两个或多个与AD相关的靶标的化合物显示出发展成为AD治疗药物的更大希望。本文中,我们报告了一种高效的两步合成法,并对新的外消旋苯并亚甲基苯衍生物作为抗氧化剂,胆碱酯酶抑制剂和β-淀粉样蛋白(Aβ1-42)聚集进行了生物学评估。根据初步筛选的结果,我们确定了15-(3-甲氧基苯基)-9,11,12,15-四氢-10 H,14 H-苯并[5,6] chromeno [2,3- d ]吡啶基[1,2一]嘧啶14 -亚胺(图3e)和16-(3-甲氧基苯基)-9,10,11,12,13,16六氢15 ħ-苯并[5',6']色烯并[2',3':4,5]嘧啶并[1,2一]氮杂-15-亚胺(3 F)作为用于AD治疗的新的潜在多目标定向配体。进一步的深入生物学分析表明,化合物3 f是一种良好的人乙酰胆碱酯酶抑制剂[IC 50 =(0.36±0.02)μm ],具有很强的抗氧化活性(3